CN1209322A - Series product of high-effective neutral calcium-supplementary preparation - Google Patents
Series product of high-effective neutral calcium-supplementary preparation Download PDFInfo
- Publication number
- CN1209322A CN1209322A CN97115225A CN97115225A CN1209322A CN 1209322 A CN1209322 A CN 1209322A CN 97115225 A CN97115225 A CN 97115225A CN 97115225 A CN97115225 A CN 97115225A CN 1209322 A CN1209322 A CN 1209322A
- Authority
- CN
- China
- Prior art keywords
- calcium
- acid
- new
- flanker
- effective neutral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000007935 neutral effect Effects 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000011575 calcium Substances 0.000 claims abstract description 36
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 36
- 238000010521 absorption reaction Methods 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 208000005392 Spasm Diseases 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 6
- 150000007524 organic acids Chemical class 0.000 claims abstract description 5
- 206010003246 arthritis Diseases 0.000 claims abstract description 4
- 208000007442 rickets Diseases 0.000 claims abstract description 4
- 230000008569 process Effects 0.000 claims abstract description 3
- 229960005069 calcium Drugs 0.000 claims description 35
- 239000013589 supplement Substances 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 206010006956 Calcium deficiency Diseases 0.000 claims description 14
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 10
- 239000003623 enhancer Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 5
- 235000010216 calcium carbonate Nutrition 0.000 claims description 5
- 208000036319 cervical spondylosis Diseases 0.000 claims description 5
- 235000015165 citric acid Nutrition 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 208000005801 spondylosis Diseases 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 4
- JPIJQSOTBSSVTP-GBXIJSLDSA-N D-threonic acid Chemical compound OC[C@@H](O)[C@H](O)C(O)=O JPIJQSOTBSSVTP-GBXIJSLDSA-N 0.000 claims description 4
- 108010001441 Phosphopeptides Proteins 0.000 claims description 4
- 229940071162 caseinate Drugs 0.000 claims description 4
- 230000035558 fertility Effects 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 206010034464 Periarthritis Diseases 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- 241000143060 Americamysis bahia Species 0.000 claims description 2
- 235000016425 Arthrospira platensis Nutrition 0.000 claims description 2
- 240000002900 Arthrospira platensis Species 0.000 claims description 2
- 241000566693 Asteriscus Species 0.000 claims description 2
- 206010005963 Bone formation increased Diseases 0.000 claims description 2
- 229910021532 Calcite Inorganic materials 0.000 claims description 2
- 241001450685 Corallium japonicum Species 0.000 claims description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 208000031220 Hemophilia Diseases 0.000 claims description 2
- 208000009292 Hemophilia A Diseases 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 2
- 241000217407 Margaritifera Species 0.000 claims description 2
- FNJSWIPFHMKRAT-UHFFFAOYSA-N Monomethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(O)=O FNJSWIPFHMKRAT-UHFFFAOYSA-N 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 2
- 239000001639 calcium acetate Substances 0.000 claims description 2
- 235000011092 calcium acetate Nutrition 0.000 claims description 2
- 229960005147 calcium acetate Drugs 0.000 claims description 2
- 239000004227 calcium gluconate Substances 0.000 claims description 2
- 235000013927 calcium gluconate Nutrition 0.000 claims description 2
- 229960004494 calcium gluconate Drugs 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 229960001714 calcium phosphate Drugs 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 210000003278 egg shell Anatomy 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 239000000174 gluconic acid Substances 0.000 claims description 2
- 235000012208 gluconic acid Nutrition 0.000 claims description 2
- 230000001788 irregular Effects 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 208000007106 menorrhagia Diseases 0.000 claims description 2
- 239000011669 selenium Substances 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 235000015170 shellfish Nutrition 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 229940082787 spirulina Drugs 0.000 claims description 2
- 239000011573 trace mineral Substances 0.000 claims description 2
- 235000013619 trace mineral Nutrition 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 201000002980 Hyperparathyroidism Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000000913 Kidney Calculi Diseases 0.000 claims 1
- 206010029148 Nephrolithiasis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- QXDHJHQRJCJRAU-UHFFFAOYSA-N calcium;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Ca].OC(=O)CC(O)(C(O)=O)CC(O)=O QXDHJHQRJCJRAU-UHFFFAOYSA-N 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 238000011020 pilot scale process Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract 1
- 201000005671 spondyloarthropathy Diseases 0.000 abstract 1
- 229930003316 Vitamin D Natural products 0.000 description 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 8
- 230000037182 bone density Effects 0.000 description 8
- 235000019166 vitamin D Nutrition 0.000 description 8
- 239000011710 vitamin D Substances 0.000 description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 description 8
- 229940046008 vitamin d Drugs 0.000 description 8
- 230000009467 reduction Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- GUPPESBEIQALOS-ZVGUSBNCSA-L calcium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Ca+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O GUPPESBEIQALOS-ZVGUSBNCSA-L 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- -1 encapsulated Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000020365 hypocalcemic rickets Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000000276 neural tube Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 230000032724 odontogenesis Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of high-effective neutral new calcium-supplementing series product and its formula, technological process and production method. Its formula composition includes 30-98% of calcium-contained compound or calcium-contained natural product, calcium absorption accelerant, 1-50% of organic acid and/or other effective component. Said invention can prevent and cure the diseases related to calciprivia, such as osteoporosis, cervical spondylopathy, arthritis, chondrification, rachitis and spasm, etc., and possesses the advantages of low cost, simple production process, high curative effect, safe and reliable and convenient application, etc..
Description
The present invention relates to the new and effective neutral calsium supplement flanker of a class and prescription, the technological process of production and method and they application in prevention and treatment multiple disease that cause by calcium deficiency or relevant with calcium deficiency.
Calcium is one of maximum most important mineral elements of people's in-vivo content.From skeleton formation, muscle contraction, heartbeat, until human thinking, in the whole vital movement of origin of life and human body, which link also lacks bound calcium.Because the dietary structure of population of China is unreasonable for a long time, calcium deficiency crowd is very extensive, reaches 800,000,000 crowd, makes calcium deficiency become a very pervasive social problem.China has been diagnosed as sufferers of osteoporosis face and has reached 8,000 ten thousand people; Whole nation child below 3 years old 9,500 ten thousand, wherein because of the calcium deficiency rickets sickness rate north 49%, south 24%; In China's 1,200,000,000 populations, between twenty and fifty calcium deficiency person disregards, and old people, child, baby, anemia of pregnant woman all need replenish the calcium in a large number, add up to population 3.3 hundred million people, by mending 400～600mg for each person every day, year mending 182.5g calcium and calculate, then year need about 60,000 tons of calcium, be equivalent to 150,000 tons of the calcium carbonate of calcic 40%.We measure living in surplus Beijing army compound 180 people's bone density recently, what bone density was good only accounts for 8.5%, and other people of 91.5% exists bone density in various degree to reduce, and moderate reduction person accounts for 43.3%, severe reduction person accounts for 26.2%, and severe and moderate reduction person account for 69.5% altogether.According to incompletely statistics, ten thousand people's bone densitometry result is similarly surplus nearly 2 years ten of Beijing.The third world no matter, still developed countries such as U.S., Europe, day, the calcium deficiency phenomenon is all more serious.It serves to show the popularity and the seriousness of calcium deficiency thus.Calcium deficiency can cause rickets, osteomalacia, spasm, hypoevolutism, haemophilia, menorrhagia or 50 various disease conditions such as irregular, climacteric syndrome, fracture, osteodynia, arthritis, cervical spondylosis, scapulohumeral periarthritis, waist and leg ache, hyperosteogeny and osteoporosis.Spaceman is the skeleton calcium loss in long-term weightlessness, also can cause osteoporosis.
Though existing tens kinds of currently marketed calcium preparation, its formulation selection and production technology respectively possess some good points, and exist following point to some extent: or the calcium content deficiency, do not reach the dosage of replenishing the calcium; Or not containing vitamin D and other calcium absorption enhancer, bioavailability is low; Or complicated component and contain the composition that some influences calcium absorption, as oxalic acid or phytic acid etc.; Particularly alkalescence is strong excessively owing to contain a large amount of calcium salts, exists side effect such as gastric irritation are bigger.So, develop a kind of calcium content height, be easy to absorb, side effect is little and the efficient neutral calcium-supplementing preparation flanker that satisfies the different crowd needs is a urgent problem.
The objective of the invention is to use rational formula, overcome the shortcoming of calcium-supplementing preparation in the past, the efficient neutral calcium-supplementing preparation flanker that formulate the novel height absorption of a class, high bioavailability, has no side effect, comprise universal, child form, fertility type, Liver and kidney type and climacteric type, to satisfy the needs of various calcium deficiency monoids.
The modern molecule medicine and pharmacology of integrated use of the present invention principle, the reasonable composition of hypothesis that the absorption ion is replenished the calcium and molecule is replenished the calcium and the strong point of American-European-Japanese calsium supplement prescription, founded the collaborative new theory of replenishing the calcium of comprehensive multidimensional, and formulated a class according to this and newly filled a prescription, it mainly consists of 30～98% calcium salt or calcic natural prodcuts, calcium absorption enhancer, organic acid and/or other functional component; Calcium containing compound in certain and calcic natural prodcuts are meant calcium carbonate or calcium chloride or lime nitrate or calcium sulfate or calcium hydrogen phosphate or calcium phosphate or calcium acetate or calcium citrate or Calcium d-tartrate or calcium gluconate or calcium lactate and eggshell or escallop or Concha Ostreae or dried small shrimps or shell or animal fresh bone or shellfish tooth or Corallium Japonicum Kishinouye or calcite or little Hai Shi or Ophicalcitum or Bal(n)phyllia sp. or Asteriscus Pseudosciaenae or Concha Haliotidis or Fossilia Spiriferis or Concha Margaritifera; Calcium absorption enhancer is meant vitamin D
2, or D
3, or hydroxyl D
3, or 1,25-dihydroxy D
3, or phosphopeptide caseinate or spirulina or other proteoglycan material; Organic acid is meant citric acid or acetic acid or lactic acid or gluconic acid or threonic acid THREONIC ACID. or ascorbic acid or malic acid or natural amino acid, and its content in prescription is 1～50%; Other functional component is meant folic acid or estrogen or does not influence the trace element of the needed by human of calcareous absorption, for example zinc, ferrum, selenium etc.The present invention is efficient neutral calsium supplement flanker, based on the collaborative new theory of replenishing the calcium of multidimensional, in light of the circumstances, the high efficiency calcium-enriching of suiting the medicine to the illness.That new and effective neutral calsium supplement flanker comprises is universal, a series of new varieties such as child form, fertility type, Liver and kidney type, climacteric type etc.; Dosage form has solid preparation and liquid preparation and iontophoresis type transdermal absorption formulations such as oral liquid, beverage such as capsule, tablet (comprising coated tablet), electuary.Their prescription difference, manufacturing process is incomplete similarity also.Universal manufacturing process is: a certain amount of ultrafine calcium carbonate is made soft material, through granulate, drying, after the screening, add citric acid and calcium absorption enhancer after a certain amount of screening again, mix homogeneously, encapsulated getting final product.Or calcium carbonate made oral liquid with phosphopeptide caseinate etc., can adopt the molecule nano technology to make.Scientific experiments is the result show: many physical chemical factors all influence vitamin D
2And D
3Stability.The present invention has guaranteed the stable existence of vitamin D in the new and effective neutral calsium supplement flanker by rational formula and meticulous preparation process, as control acid and measure (being no more than 20%), temperature (less than 28 ℃), humidity (less than 40%), avoid illumination, avoided the measures such as stabilizing agent of long-time ingress of air and wet gas or adding appropriate vitamin D.Stability experiment and accelerated stability test result show: this prescription is stable, and the shelf-life can reach more than 2 years.
Human body and zoopery result show: the present invention is new and effective neutral calsium supplement flanker human absorptivity height, bioavailability height, the efficient of replenishing the calcium height, to oral cavity stomach function regulating intestinal mucosa nonirritant almost, and pH value is neutral.Its series of products have overcome the serious side effects of popular many kinds of replenishing the calcium on the market (comprise and stimulate stomach even cause gastroptosis, gastric ulcer), overcome some kind calcium content deficiencies or do not contain vitamin D or other calcium absorption enhancer, be difficult for having solved the absorption of liver, nephrotic's vitamin D metabolism ability, calcium and having utilized the ability extremely to hang down this difficult problem for defectives, particularly the present invention (Liver and kidney type) such as human body are absorbed, the calcium bioavailability is low.The present invention's (fertility type) can use for the women of child-bearing age, and not only high efficiency calcium-enriching also can prevent following fetal neural tube deformity, and cardiovascular system is also had big benefit.The most outstanding is, vitamin D and acid this difficult problem that can not coexist has been captured in birth of the present invention.Be suitable for child, teenager, anemia of pregnant woman, menopausal women and other person in middle and old age and replenish the calcium, the while also can be used for health care and spaceman is replenished the calcium.Take for a long time help to prevent with treat multiple because of calcium deficiency causes or the disease relevant with calcium deficiency, as chondrify disease, rickets, cervical spondylosis, scapulohumeral periarthritis, arthritis, spasm, numb hand and foot, fall tooth alopecia, sore waist and aching in the waist and the back, bone growth is bad, osteoporosis is easy to break, tooth development deformity etc.Cost of the present invention is low, instant effect, curative effect height, taking convenience and safe and reliable.
The present invention can be further specified by the example of following enforcement.
Embodiment 1
One of manufacturing process of the neutral calsium supplement of general-purpose highly effective
Get superfine powder CaCO
3600.0g, add 10% starch and 10% dextrin adhesive and make soft material, granulation, 100 ℃ of dry 8h, cross 60 mesh sieve granulate, add 60.00g citric acid (crossing 80 mesh sieves), under the moistureproof condition of lucifuge, be temperature less than 28 ℃, humidity adds the 0.003125g vitamin D less than 40%
3, by the mixing of sieving repeatedly of the equivalent method of progressively increasing,, or handled 5～10 minutes greater than 600 Gausses' magnetic field magnetisation through field intensity again with mixed at high speed pellet fabrication device mix homogeneously, after adding desiccant, encapsulated, aluminium foil sealing or bottling seal, and lucifuge is stored.
Embodiment 2
One of manufacturing process of the efficient neutral calsium supplement of child form
Take by weighing 500g ultra micro CaCO
3, place the container of containing the 50L distilled water, add the 800g citric acid and stir, make it whole dissolvings, add Mel 1L again, phosphopeptide caseinate 50g, zinc gluconate 500g, ferrous lactate 80g, ethyl hydroxybenzoate 5g stirs, dress 10mL bottle, and preserve sealing, sterilization back.
Embodiment 3
Clinical efficacy with the reduction of new and effective neutral calsium supplement treatment bone density, cervical spondylosis, shank spasm and waist lower limb ache disease
Get certain the two compound bone density reduction persons of army, 180 example, cervical vertebra case 15 examples, shank spasm 28 examples, waist and leg ache 25 examples, severe person takes medicine 2 every day, each 1.In, slight person once a day, each one, be 3 months the course of treatment.Statistical result shows that bone density stops reduction person and accounts for 20% of former bone density reduction total number of persons, and bone density is stablized rise person and accounted for 70% of sum, and total effective rate reaches 90%; Patient's sx of cervical spondylosis, shank spasm, waist and leg ache or disappearance account for 95%.
Embodiment 4
New and effective neutral calsium supplement and U.S. Caltrate-D are to the irritating comparison of gastric mucosa of rat
The new and effective neutral calsium supplement of the present invention with compare through the rather well received products C altrate-D that replenishes the calcium of the U.S. of FDA approval, littler to the stimulation of gastric mucosa of rat.Every day, oral administration was respectively 90mg/kg, 180mg/kg, and with anatomical lens and microscopic examination, the present invention does not have tangible hyperemization to gastric mucosa, and takes Caltrate-D, has slight and tangible congested phenomenon to take place respectively.Every day during oral administration 270mg/kg (with respect to 40 times of people's consumption), calcium Wei Kang only causes the gastric mucosa of rat mild hyperaemia, and Caltrate-D causes that also gastric mucosal cell comes off.The result shows: the present invention almost has no side effect than littler, the better effects if of U.S.'s Caltrate-D side effect.
Embodiment 5
Mtd test of the present invention
According to national new drug declaration requirement, designed rat and mice to mtd test of the present invention with mice and two kinds of animal oral administration routes of rat respectively, measure its maximum dosage.The result shows, the present invention irritates the dosage of stomach for 1 time on the one greater than 15g/kg to rat, rat is irritated the dosage of stomach for 3 times on the one greater than 45g/kg, mice is irritated the dosage of stomach for 1 time on the one greater than 50g/kg, the dosage that mice 3 times on the one is irritated stomach is greater than 150g/kg, there is no mice, rat has abnormal response.Animation is still good.This shows that reality of the present invention is nontoxic, and is safe and reliable.
Claims (8)
1. the new and effective neutral calcium-supplementing preparation of a class, comprise universal, child form, fertility type, Liver and kidney type and climacteric type.Its main constituent is 30～98% calcium containing compound or calcic natural prodcuts, calcium absorption enhancer, 1～50% organic acid and/or other functional component.
2. according to the new and effective neutral calsium supplement flanker of claim 1, wherein said calcium containing compound and calcic natural prodcuts are meant calcium carbonate or calcium phosphate or calcium acetate or Citric acid calcium or calcium gluconate or calcium lactate or eggshell or escallop or Concha Ostreae or dried small shrimps or shell or animal fresh bone or shellfish tooth or Corallium Japonicum Kishinouye or calcite or little Hai Shi or Ophicalcitum or Bal(n)phyllia sp. or Asteriscus Pseudosciaenae or Concha Haliotidis or Fossilia Spiriferis or Endoconcha Sepiae or Concha Margaritifera.
3. according to the new and effective neutral calsium supplement flanker of claim 1, wherein said calcium absorption enhancer is meant vitamin D
2, or D
3, or hydroxyl D
3, or 1,25-dihydroxy D
3, or phosphopeptide caseinate or spirulina or other proteoglycan compounds.
4. according to the new and effective neutral calsium supplement flanker of claim 1, wherein said organic acid is meant citric acid or acetic acid or lactic acid or gluconic acid or threonic acid THREONIC ACID. or ascorbic acid or malic acid or natural amino acid.
5. according to the new and effective neutral calsium supplement flanker in the claim 1, wherein said other functional component is meant folic acid or estrogen or does not influence the trace element of the needed by human of calcium absorption, as selenium, zinc, ferrum etc.
6. the several formulations pilot scale of the new and effective neutral calsium supplement flanker of claim 1 and/or the technological process of production and method.Wherein said several formulations is meant capsule or solid preparation and liquid preparation and iontophoresis type transdermal absorption formulations such as oral liquid, beverage such as tablet or electuary.
7. the new and effective neutral calsium supplement flanker of claim 1 is in prevention with treat multiple calcium deficiency or the disease relevant with calcium deficiency, comprises that rickets, chondrify disease, hypoevolutism, haemophilia, menorrhagia or irregular, climacteric syndrome, fracture, osteodynia, arthritis, cervical spondylosis, scapulohumeral periarthritis, Kaschin-Beck disease, hyperparathyroidism, waist and leg ache, spasm, hyperosteogeny and osteoporosis reach the application in a series of syndromes that cause thus.
8. application and the application in prevention and treatment liver-kidney diseases patient calcium deficiency of the new and effective neutral calsium supplement flanker of claim 1 in cardiovascular disease such as prophylaxis of hypertension, heart disease, arteriosclerosis and renal calculus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97115225A CN1067250C (en) | 1997-08-21 | 1997-08-21 | Series product of high-effective neutral calcium-supplementary preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97115225A CN1067250C (en) | 1997-08-21 | 1997-08-21 | Series product of high-effective neutral calcium-supplementary preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1209322A true CN1209322A (en) | 1999-03-03 |
| CN1067250C CN1067250C (en) | 2001-06-20 |
Family
ID=5173217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97115225A Expired - Fee Related CN1067250C (en) | 1997-08-21 | 1997-08-21 | Series product of high-effective neutral calcium-supplementary preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1067250C (en) |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1458372A4 (en) * | 2001-07-03 | 2007-04-25 | Juneng Industry Co Ltd | Calcium l-threonate for preventing or treating cartilage related diseases |
| CN100418575C (en) * | 2005-11-21 | 2008-09-17 | 陈斌 | Complex calcium preparations for astronauts |
| CN102133230A (en) * | 2011-03-15 | 2011-07-27 | 南京中医药大学 | Compound mactra veneriformis organic calcium preparation and preparation method thereof |
| CN102151285A (en) * | 2010-02-11 | 2011-08-17 | 北京新世纪达康生物科技开发有限责任公司 | Neutral calcium supplement preparation |
| CN102178293A (en) * | 2011-04-07 | 2011-09-14 | 解保领 | Health-care drinks capable of improving immunity in human bodies and preparation method thereof |
| CN102397296A (en) * | 2010-09-17 | 2012-04-04 | 南京星银药业集团有限公司 | Cuttlebone dispersible tablet and preparation method thereof |
| CN102524785A (en) * | 2012-02-08 | 2012-07-04 | 姚鼎山 | Negative hydrogen ion powder and preparation method thereof |
| CN102599607A (en) * | 2012-03-16 | 2012-07-25 | 常熟市汇丰食品有限公司 | Walnut calcium supplement effervescing preparation |
| CN102762113A (en) * | 2009-11-30 | 2012-10-31 | 帕拉法姆有限公司 | Biologically active food additive for the prophylaxis of osteoporosis diseases |
| CN102824596A (en) * | 2011-11-20 | 2012-12-19 | 张玉丹 | Medical oral traditional Chinese medicinal capsule for treating renal calculus and ureteral calculus |
| CN102987404A (en) * | 2012-08-21 | 2013-03-27 | 苏州谷力生物科技有限公司 | Food additive for promoting calcium absorption |
| CN103202483A (en) * | 2012-01-11 | 2013-07-17 | 浙江康恩贝健康产品有限公司 | Nutritional composition for calcium supplement |
| US8592480B2 (en) | 2006-07-21 | 2013-11-26 | Lyne Laboratories, Inc. | Liquid compositions of calcium acetate |
| CN105056209A (en) * | 2015-07-16 | 2015-11-18 | 中山大学深圳研究院 | Application of pearl mother protein N16 in preparing osteogenic activity medicine |
| CN105056210A (en) * | 2015-07-16 | 2015-11-18 | 中山大学深圳研究院 | Application of concha margaritiferallsta protein N16 in preparing drug for inhibiting osteoclastic activity |
| CN110074417A (en) * | 2019-05-09 | 2019-08-02 | 五邑大学 | A kind of calcium tartrate agent and preparation method thereof |
| CN112293634A (en) * | 2019-08-01 | 2021-02-02 | 广州富诺营养科技有限公司 | Seaweed powder solid beverage and preparation method thereof |
| CN112754019A (en) * | 2020-12-23 | 2021-05-07 | 河南九天生物科技有限公司 | Composition containing 25 hydroxyl d3 and calcium gluconate and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2724844B1 (en) * | 1994-09-23 | 1997-01-24 | Innothera Lab Sa | VITAMIN-CALCIUM THERAPEUTIC COMBINATION, PROCESS FOR OBTAINING SAME AND USE THEREOF |
-
1997
- 1997-08-21 CN CN97115225A patent/CN1067250C/en not_active Expired - Fee Related
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1458372A4 (en) * | 2001-07-03 | 2007-04-25 | Juneng Industry Co Ltd | Calcium l-threonate for preventing or treating cartilage related diseases |
| CN100418575C (en) * | 2005-11-21 | 2008-09-17 | 陈斌 | Complex calcium preparations for astronauts |
| US9089528B2 (en) | 2006-07-21 | 2015-07-28 | Lyne Laboratories, Inc. | Liquid compositions of calcium acetate |
| US8591938B2 (en) | 2006-07-21 | 2013-11-26 | Lyne Laboratories, Inc. | Liquid compositions of calcium acetate |
| US8592480B2 (en) | 2006-07-21 | 2013-11-26 | Lyne Laboratories, Inc. | Liquid compositions of calcium acetate |
| CN102762113A (en) * | 2009-11-30 | 2012-10-31 | 帕拉法姆有限公司 | Biologically active food additive for the prophylaxis of osteoporosis diseases |
| CN105212234A (en) * | 2009-11-30 | 2016-01-06 | 帕拉法姆有限公司 | For preventing osteoporotic BA food supplement |
| CN105146514A (en) * | 2009-11-30 | 2015-12-16 | 帕拉法姆有限公司 | Biologically active food additive for the prophylaxis of osteoporosis diseases |
| CN102151285B (en) * | 2010-02-11 | 2013-01-16 | 北京新世纪达康生物科技开发有限责任公司 | Neutral calcium supplement preparation |
| CN102151285A (en) * | 2010-02-11 | 2011-08-17 | 北京新世纪达康生物科技开发有限责任公司 | Neutral calcium supplement preparation |
| CN102397296A (en) * | 2010-09-17 | 2012-04-04 | 南京星银药业集团有限公司 | Cuttlebone dispersible tablet and preparation method thereof |
| CN102133230A (en) * | 2011-03-15 | 2011-07-27 | 南京中医药大学 | Compound mactra veneriformis organic calcium preparation and preparation method thereof |
| CN102133230B (en) * | 2011-03-15 | 2012-10-24 | 南京中医药大学 | Compound mactra veneriformis organic calcium preparation and preparation method thereof |
| CN102178293B (en) * | 2011-04-07 | 2013-01-02 | 解保领 | Health-care drinks capable of improving immunity in human bodies and preparation method thereof |
| CN102178293A (en) * | 2011-04-07 | 2011-09-14 | 解保领 | Health-care drinks capable of improving immunity in human bodies and preparation method thereof |
| CN102824596B (en) * | 2011-11-20 | 2014-03-12 | 秦玉堂 | Medical oral traditional Chinese medicinal capsule for treating renal calculus and ureteral calculus |
| CN102824596A (en) * | 2011-11-20 | 2012-12-19 | 张玉丹 | Medical oral traditional Chinese medicinal capsule for treating renal calculus and ureteral calculus |
| CN103202483A (en) * | 2012-01-11 | 2013-07-17 | 浙江康恩贝健康产品有限公司 | Nutritional composition for calcium supplement |
| CN102524785A (en) * | 2012-02-08 | 2012-07-04 | 姚鼎山 | Negative hydrogen ion powder and preparation method thereof |
| CN102599607A (en) * | 2012-03-16 | 2012-07-25 | 常熟市汇丰食品有限公司 | Walnut calcium supplement effervescing preparation |
| CN102987404A (en) * | 2012-08-21 | 2013-03-27 | 苏州谷力生物科技有限公司 | Food additive for promoting calcium absorption |
| CN105056209A (en) * | 2015-07-16 | 2015-11-18 | 中山大学深圳研究院 | Application of pearl mother protein N16 in preparing osteogenic activity medicine |
| CN105056210A (en) * | 2015-07-16 | 2015-11-18 | 中山大学深圳研究院 | Application of concha margaritiferallsta protein N16 in preparing drug for inhibiting osteoclastic activity |
| CN110074417A (en) * | 2019-05-09 | 2019-08-02 | 五邑大学 | A kind of calcium tartrate agent and preparation method thereof |
| CN112293634A (en) * | 2019-08-01 | 2021-02-02 | 广州富诺营养科技有限公司 | Seaweed powder solid beverage and preparation method thereof |
| CN112293634B (en) * | 2019-08-01 | 2023-01-17 | 广州富诺营养科技有限公司 | Seaweed powder solid beverage and preparation method thereof |
| CN112754019A (en) * | 2020-12-23 | 2021-05-07 | 河南九天生物科技有限公司 | Composition containing 25 hydroxyl d3 and calcium gluconate and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1067250C (en) | 2001-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1067250C (en) | Series product of high-effective neutral calcium-supplementary preparation | |
| CZ247795A3 (en) | Complementary dietic preparation | |
| WO2017101887A1 (en) | Healthcare pharmaceutical preparation having magnesium supplementation and anti-oxidation effects, and preparation method for healthcare pharmaceutical preparation | |
| CN101268835A (en) | Nutrition high calcium medicinal granule for children and preparing technique | |
| RU2309751C1 (en) | Method for treating the disorders of mineral metabolism at arthritis, or osteochondrosis, or rickets, or arthrosis, or osteoporosis | |
| JP2011510922A (en) | Formulation containing calcium, magnesium, zinc and vitamin D3 for prevention and recovery of osteoporosis | |
| CN107373274A (en) | Vitamin c effervescent tablet and preparation method thereof | |
| CN1208351A (en) | Composition containing diosgenin | |
| CN101268836B (en) | Nutrition high calcium medicinal granule and preparing technique | |
| CN1212126C (en) | Nano-hydroxyapatite calcium supplement | |
| WO2001022943A1 (en) | A slow release pharmaceutical composition comprising a magnesium oxychloride cement | |
| CN100515430C (en) | Pharmaceutical preparation for supplementing calcium, magnesium and vitamin D | |
| CN114306383A (en) | Growth-promoting pharmaceutical composition for improving solubility of calcium hydrogen phosphate and preparation process thereof | |
| CN1081031C (en) | Calcium tablet | |
| CN1415308A (en) | Nano selenium of amino acid and its preparation method | |
| CN101797385B (en) | Oral calcium pharmaceutical composition | |
| CN102000110A (en) | Composition used for preventing or treating bone and joint diseases and preparation method thereof | |
| RU2356546C1 (en) | Sygethin-based pharmaceutical structure for osteoporosis prevention and treatment (versions) | |
| CN105533699A (en) | Compound for supplementing zinc and vitamin in children as well as preparation method and application thereof | |
| CN100515429C (en) | Calcium and magnesium supplementing medicinal preparation | |
| RU2323599C1 (en) | Biologically active food additive and its production method | |
| CN104872650A (en) | Tablets containing multiple vitamins and mineral substances suitable for children and teenagers | |
| CN1509721A (en) | Composition containing plant estrogen and amino glucose against bone retrograde affection and preparation | |
| CN1303904C (en) | Olive calcium tablet | |
| CN108159073A (en) | A kind of Calci-Mix |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Applicant after: Inst. of Military Medicine, Rear-Service Department, General Equipment Departmen Applicant before: Military Medicine Inst., Logistics Department, Commission of Science, Technology |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: MILITARY MEDICINE INSTITUTE, LOGISTICS DEPARTMENT, CHINESE PLA COMMISSIONOF SCIENCE, TECHNOLOGY TO: MILITARY MEDICINE INSTITUTE,LOGISTICS DEPARTMENT, CHINESE PLA GENERAL EQUIPMENT DEPARTMENT |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |